Bioarchitech

What Bioarchitech does

Bioarchitech is a preclinical-stage immuno-oncology therapeutics company headquartered in Oxford, United Kingdom, founded in 2021 by Kevin Maskell, Geoff Hale, Lili Wang, and Hannah Chen. The company develops multifunctional cancer immunotherapies by mining the genetic code of viruses, with the explicit thesis that single-mechanism oncology drugs are insufficient to cure most patients. Its pipeline comprises two distinct assets: BA-V151, an intravenous modified Vaccinia virus engineered to selectively replicate within tumour cells and armed with a proprietary CD47-targeting single-domain antibody (sdAb) that blocks the "don't eat me" signal to enable immune phagocytosis (designed for metastatic cancer); and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic that triggers immunogenic cell death and converts the tumour into an in-situ personalised vaccine prior to surgery (designed for early-stage solid tumours, initially oesophageal and lung cancer).

The platform rests on two differentiated technical components: a CD47-blocking sdAb expressed from within an oncolytic viral vector, which addresses the long-standing toxicity/efficacy trade-off of systemic CD47 blockade; and a saRNA delivery system that achieves full mechanism of action within approximately one to three days at vaccine-level cost. Preclinical proof-of-concept data for BA-V151 demonstrated complete protection in an aggressive metastasising cancer model versus 20–50% mortality in untreated controls, and the anti-CD47 sdAb has shown enhanced antibody-dependent cellular phagocytosis when combined with trastuzumab (Herceptin®). Both candidates are protected by UK patent applications filed in January 2025.

Bioarchitech currently generates no commercial revenue. Its go-to-market model centres on biopharma licensing, co-development, and contract manufacturing organisation (CMO) partnerships, supported by participation in industry partnering events (JPM Biotech Showcase, BioTrinity, ChinaBio, Oncolytic Virotherapy Summit). The end beneficiaries, if approved, would be oncology patients with metastatic disease (BA-V151) or early-stage solid tumours at risk of spreading (BA-R166). The company operates from the Oxford Trust's Wood Centre for Innovation and has secured a UKHSA/ECACC material license to develop a scalable manufacturing platform for BA-V151.

Name

Bioarchitech

Legal name

Bioarchitech Ltd

Website

https://bioarchitech.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Bioarchitech is a preclinical-stage Oxford-based immuno-oncology biotech developing two multifunctional cancer immunotherapies: BA-V151 (an oncolytic Vaccinia virus blocking CD47 for metastatic cancer) and BA-R166 (an intratumoural self-amplifying RNA neoadjuvant for early-stage solid tumours prior to surgery).

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Oncolytic virus therapy
• Cancer immunotherapy
• Self-amplifying RNA therapeutics
• Viral vector biopharmaceuticals
• Immuno-oncology pipeline

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Others, Infrastructure

Revenue model

1. Therapeutic pipeline development and out-licensing: As a preclinical-stage immuno-oncology biotech, Bioarchitech has no current commercial revenue. The company is advancing BA-V151 and BA-R166 through preclinical and towards clinical development, with the intention of out-licensing or co-developing assets with pharmaceutical partners, or pursuing independent commercialisation upon clinical validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Bioarchitech is a preclinical-stage immuno-oncology biotechnology company engineering multifunctional cancer immunotherapies by mining the genetic code of viruses. Its two pipeline assets are BA-V151, an intravenous modified Vaccinia virus armed with a proprietary anti-CD47 single-domain antibody for metastatic cancer, and BA-R166, an intratumoural self-amplifying RNA (saRNA) immunotherapeutic designed as a neoadjuvant to turn early-stage tumours into personalised vaccines prior to surgery.

Product overview

Bioarchitech is developing two distinct cancer immunotherapy assets as part of its pipeline: BA-V151 is an intravenous viral therapy using a modified Vaccinia virus engineered with a proprietary anti-CD47 single-domain antibody, designed for metastatic cancers with comprehensive systemic reach; BA-R166 is a direct intratumoural injection of self-amplifying RNA that acts as a neo-adjuvant immunotherapy, turning tumours into personalised in-situ vaccines prior to surgery for early-stage cancers. Both candidates are multifunctional immunotherapies that both kill cancer cells and induce immunity against metastatic disease.

Differentiator

Problem solved

Functional benefit

Products and services

• BA-V151
• BA-R166

Quantifiable outcome

• In proof-of-concept experiments, BA-V151 achieved complete protection in an aggressive metastasising cancer model where 20–50% of untreated animals typically die from metastases.
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• UK Health Security Agency (UKHSA) / ECACCcoreTechnology or Integration · 1 March 2026Bioarchitech secured a material license from UKHSA's European Collection of Authenticated Cell Cultures (ECACC) for a mammalian cell line to be developed as a scalable, high-yield viral manufacturing platform and for the Vaccinia virus vector backbone of BA-V151. The licensed cell line is pre-adapted to suspension conditions, improving scalability over traditional adherent cell lines. Bioarchitech plans to further optimise the platform under serum-free growth conditions for regulatory suitability, then establish a research cell bank for transfer to a CMO partner for process development.
• Engineering Biology Centre for Doctoral Training (EngBioCDT)coreStrategic or Co-development Partner · 1 October 2024Bioarchitech acts as an industry partner for the EngBioCDT at the University of Oxford, integrating industry insights into academic training. Dr Andri Vasou delivered lectures on the immune system. Bioarchitech collaborates with Associate Professor Malavika Nair on short-term student research projects investigating innovative approaches to mRNA delivery, focusing on alternative delivery vehicles that improve efficacy and cancer targeting.
• Greaves BrewsterminorOthersListed as a partner on Bioarchitech's partners page. Likely provides patent/IP legal services.
• University of OxfordcoreStrategic or Co-development PartnerListed as a partner on Bioarchitech's partners page. Bioarchitech collaborates with University of Oxford researchers including Malavika Nair (EngBioCDT) and has academic founders with Oxford affiliations. The company is based at Oxford and leverages Oxford's research ecosystem.
• Oxford TechnologyminorOthersListed as a partner on Bioarchitech's partners page. Associated with Oxford's technology and startup ecosystem.
• BioEscalatorminorOthersListed as a partner on Bioarchitech's partners page. Bioarchitech was previously housed at the BioEscalator (Oxford's bioscience incubator) before moving to the Wood Centre for Innovation in July 2024.
• Oxford Trust (Wood Centre for Innovation)coreOthersListed as a partner on Bioarchitech's partners page. The Oxford Trust operates the Wood Centre for Innovation (WCFI) where Bioarchitech is headquartered. Bioarchitech moved to WCFI in July 2024 for larger lab space to accommodate team expansion.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Moderna: Commercial-stage mRNA company with a personalised cancer vaccine (mRNA-4157/V940 in Phase 3 with Merck). Broad incumbent competing for the personalised cancer vaccine value pool that BA-R166 is positioned to address via a cheaper, off-the-shelf intratumoural saRNA approach.
• BioNTech: Commercial-stage immuno-oncology and infectious disease mRNA company with FixVac, iNeST, and other cancer vaccine platforms (including the personalised neoantigen vaccine programme with Genentech). Broad incumbent relevant to BA-R166's personalised cancer vaccine thesis and to the broader oncolytic-immunotherapy space.

Direct peers

• ALX Oncology: Clinical-stage immuno-oncology company developing a CD47-blocking therapeutic (evorpacept) with a differentiated high-affinity mechanism. Direct peer in the CD47 checkpoint space relevant to Bioarchitech's anti-CD47 sdAb payload on BA-V151.
• Replicate Bioscience: Clinical-stage biotech developing self-amplifying RNA therapeutics for cancer and other diseases. Direct peer sharing the saRNA modality relevant to BA-R166 with a comparable preclinical-to-early-clinical stage profile.
• VaxEquity: Imperial College London spin-out developing self-amplifying RNA vaccines for infectious disease and oncology. Direct peer to BA-R166 given shared saRNA modality and UK academic origin in the same broader RNA ecosystem.
• Genelux Corporation: Clinical-stage immuno-oncology company developing oncolytic vaccinia virus-based therapies (Olvi-Vec) delivered intravenously and intrapleurally for cancer. Direct peer given Bioarchitech's modified Vaccinia virus backbone (BA-V151) and intravenous delivery approach.
• Replimune: Clinical-stage biotech developing a portfolio of oncolytic viruses (RP1, RP2, RP3) based on an engineered herpes simplex virus platform for solid tumours. Directly comparable to Bioarchitech's BA-V151 as a viral-immunotherapy for cancer with mechanism of action combining direct oncolysis and immune activation.
• Imugene: Clinical-stage immuno-oncology company developing oncolytic virotherapy (VAXINIA / CF33) and B-cell immunotherapies for solid tumours. Direct peer through shared focus on oncolytic viral platforms for cancer immunotherapy with intratumoural and intravenous routes.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with a self-amplifying RNA (saRNA) platform including oncology and infectious disease programs. Direct peer to BA-R166 as the most advanced saRNA developer, sharing the same core modality and cost/speed advantages.

Regional players

• OXB (formerly Oxford BioMedica): UK-based cell and gene therapy CDMO and developer with lentiviral vector manufacturing expertise. Regional peer given shared Oxford/UK biotech ecosystem, prior overlap with Bioarchitech alumni (Ines Loureiro), and relevance to viral vector manufacturing for BA-V151.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioarchitech-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioarchitech